
    
      This trial was a non-randomized, multi-center, prospective study of subjects with
      symptomatic, paroxysmal atrial fibrillation (PAF). The purpose of this study was to
      investigate and confirm the safety, efficacy and efficiency of the Medtronic Ablation
      FrontiersÂ® Cardiac Ablation System when used for the treatment of paroxysmal AF. The trial
      was conducted over a 2 year period with enrollment occurring between 4 October 2007 and 1
      December 2008.
    
  